Early phase development of anti-drug-antibodies in rheumatoid arthritis patients

Academisch Medisch Centrum0 个研究点目标入组 280 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

暂无简介。

•Male and female patients of more than 18 years old diagnosed with rheumatoid arthritis according to 2010 ACR/EULAR criteria - Patient for whom the Treating Physician has decided to prescribe a BP in the usual manner in accordance with the terms of the marketing authorization and independently from entry into this study. - Having given written informed consent prior to undertaking any study-related procedures. - Covered by a health insurance system where applicable, and/or in compliance with the recommendations of the national laws in force relating to biomedical research.

•Received treatment with the same BP before (use of other BP previously is allowed). - Included in another study protocol. - Under any administrative or legal supervision. - Conditions/situations such as: • Patients with conditions/concomitant diseases making them non evaluable for the primary endpoint • Impossibility to meet specific protocol requirements (e.g. blood sampling) • Patient is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the protocol • Uncooperative or any condition that could make the patient potentially non-compliant to the study procedures

发起方